Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
Standard
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. / Dimopoulos, M A; Leleu, X; Palumbo, A; Moreau, P; Delforge, M; Cavo, M; Ludwig, H; Morgan, G J; Davies, F E; Sonneveld, P; Schey, S A; Zweegman, S; Hansson, M; Weisel, K; Mateos, M V; Facon, T; Miguel, J F S.
in: LEUKEMIA, Jahrgang 28, Nr. 8, 08.2014, S. 1573-85.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
AU - Dimopoulos, M A
AU - Leleu, X
AU - Palumbo, A
AU - Moreau, P
AU - Delforge, M
AU - Cavo, M
AU - Ludwig, H
AU - Morgan, G J
AU - Davies, F E
AU - Sonneveld, P
AU - Schey, S A
AU - Zweegman, S
AU - Hansson, M
AU - Weisel, K
AU - Mateos, M V
AU - Facon, T
AU - Miguel, J F S
PY - 2014/8
Y1 - 2014/8
N2 - In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, whereas dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopaenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism is provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.
AB - In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, whereas dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopaenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism is provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.
KW - Age Factors
KW - Clinical Trials as Topic
KW - Dexamethasone
KW - Drug Administration Schedule
KW - Humans
KW - Immunologic Factors
KW - Infection
KW - Multiple Myeloma
KW - Neutropenia
KW - Peripheral Nervous System Diseases
KW - Quality of Life
KW - Thalidomide
KW - Venous Thromboembolism
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - 10.1038/leu.2014.60
DO - 10.1038/leu.2014.60
M3 - SCORING: Review article
C2 - 24496300
VL - 28
SP - 1573
EP - 1585
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 8
ER -
